Confident Buy Rating for Evolus Amid Strategic Growth and Market Stability

Leerink Partners analyst Marc Goodman has maintained their bullish stance on EOLS stock, giving a Buy rating on May 28.

Marc Goodman has given his Buy rating due to a combination of factors that reflect confidence in Evolus’s strategic direction and market position. Despite the recent departure of CFO Sandra Beaver, Goodman remains optimistic about the company’s trajectory, as there are no indications of internal issues that might affect its operations. CEO David Moatazedi has expressed assurance in the company’s ability to maintain its market share gains in the US toxin market, which is experiencing low single-digit growth.
Goodman acknowledges potential investor concerns regarding broader macroeconomic trends, such as market volatility and consumer sentiment. However, he believes that Evolus’s management team is well-equipped to navigate these challenges and continue executing their strategy effectively. The anticipated launch of a second product line, Evolysse, adds to the positive outlook, reinforcing Goodman’s confidence in the company’s future performance.

According to TipRanks, Goodman is a 3-star analyst with an average return of 2.3% and a 45.01% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Aldeyra Therapeutics, Evolus, and Biohaven Ltd..

In another report released on May 28, Mizuho Securities also reiterated a Buy rating on the stock with a $25.00 price target.